SignatureFD’s C4 Therapeutics CCCC Stock Holding History

SignatureFD’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16	Closed	-$1K	–	3126
2021 Q3	$1K	Buy	+16	New	+$685	﹤0.01%	2790

Other funds holding CCCC

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SignatureFD's CCCC Position: Q4 2021 in Review

SignatureFD sold out of C4 Therapeutics (CCCC) in Q4 2021, closing a stake of 16 shares — an estimated $1K sold.

SignatureFD first reported a position in CCCC in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 119 funds tracked by Wall St. Rank hold CCCC as of Q4 2021.

SignatureFD reported no remaining C4 Therapeutics position as of Q4 2021 after selling out during the quarter.
SignatureFD sold 16 C4 Therapeutics shares in Q4 2021, an estimated $1K.
SignatureFD first reported a position in C4 Therapeutics in Q3 2021 and held it in 1 quarter.
SignatureFD's C4 Therapeutics position peaked at $1K in Q3 2021.
119 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2021.

Based on SignatureFD's 13F filing for Q4 2021, filed 25 Jan 2022.